Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial

医学 中止 内科学 银屑病面积及严重程度指数 不利影响 银屑病 安慰剂 斑块性银屑病 随机对照试验 临床试验 胃肠病学 皮肤病科 病理 替代医学
作者
Jianzhong Zhang,Yangfeng Ding,Ping Wang,Linfeng Li,Weili Pan,Yan Lü,Hao Cheng,Xian Jiang,Ji‐Chen Ho,Shuping Guo,L. Liu,Arkendu Chatterjee,Renata M Kisa,Subhashis Banerjee
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:192 (3): 402-409 被引量:10
标识
DOI:10.1093/bjd/ljae406
摘要

Abstract Background Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, is approved in the USA, the European Union, Japan, South Korea, China and other countries for the treatment of moderate-to-severe plaque psoriasis. Objectives To evaluate the efficacy and safety of deucravacitinib in Asian patients with moderate-to-severe plaque psoriasis. Methods In the 52-week blinded phase III POETYK PSO-3 trial (NCT04167462), patients were randomized 1 : 2 to placebo (n = 74) or deucravacitinib 6 mg once daily (n = 146) for 16 weeks followed by deucravacitinib alone. Co-primary endpoints were the achievement of a ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician Global Assessment score of 0 (clear) or 1 (almost clear; sPGA 0/1) at week 16. Efficacy and safety were evaluated throughout. Results At week 16, significantly higher proportions of patients receiving deucravacitinib compared with placebo achieved PASI 75 (68.8% vs. 8.1%; P < 0.001) and sPGA 0/1 (55.6% vs. 6.8%; P < 0.001). Response rates with deucravacitinib were maintained through week 52. Common adverse events (AEs) included upper respiratory tract infection and nasopharyngitis. Serious AE and discontinuation rates were low. Conclusions Deucravacitinib was efficacious and well tolerated in Asian patients with moderate-to-severe plaque psoriasis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Suer完成签到 ,获得积分10
刚刚
刚刚
刚刚
AaronLiu完成签到 ,获得积分10
刚刚
在水一方应助季风采纳,获得10
1秒前
2秒前
2秒前
忘川发布了新的文献求助10
2秒前
3秒前
3秒前
Z118发布了新的文献求助10
3秒前
慕青应助古月衣采纳,获得10
3秒前
5秒前
ygtrece1337完成签到,获得积分20
5秒前
zhuzhu5181发布了新的文献求助10
7秒前
悦耳的菠萝完成签到,获得积分10
7秒前
香蕉觅云应助贪玩的秋柔采纳,获得10
8秒前
8秒前
8秒前
桐桐应助张零采纳,获得10
8秒前
1111发布了新的文献求助10
8秒前
白衣未央完成签到,获得积分10
9秒前
9秒前
科研通AI6.3应助123采纳,获得10
10秒前
晴枫3648发布了新的文献求助10
11秒前
11秒前
CipherSage应助豆豆采纳,获得10
11秒前
12秒前
12秒前
1111完成签到,获得积分10
12秒前
充电宝应助念安采纳,获得10
12秒前
13秒前
13秒前
yjt发布了新的文献求助10
13秒前
13秒前
soOK完成签到,获得积分10
14秒前
Z118完成签到,获得积分10
14秒前
zyq发布了新的文献求助10
14秒前
15秒前
1111发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Metallurgy at high pressures and high temperatures 2000
Tier 1 Checklists for Seismic Evaluation and Retrofit of Existing Buildings 1000
PowerCascade: A Synthetic Dataset for Cascading Failure Analysis in Power Systems 1000
The Organic Chemistry of Biological Pathways Second Edition 1000
Signals, Systems, and Signal Processing 610
An Introduction to Medicinal Chemistry 第六版习题答案 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6332255
求助须知:如何正确求助?哪些是违规求助? 8148789
关于积分的说明 17103892
捐赠科研通 5387949
什么是DOI,文献DOI怎么找? 2856338
邀请新用户注册赠送积分活动 1833903
关于科研通互助平台的介绍 1685018